Discover

VRCA
Verrica Pharmaceuticals Inc.
4.11
2 x 3.40
2 x 5.91
bid
ask
-
0.07
1.67%
2 @ 04:00 PM
4.19 +0.08 (1.95%)
Ytd-50.54%
1y-4.42%
4.06
day range
4.37
3.28
52 week range
9.10
Open4.37Prev Close4.18Low4.06High4.37Mkt Cap70.60M
Vol46.55KAvg Vol62.56KEPS-1.75P/EN/AForward P/E-1.19
Beta1.46Short Ratio3.19Inst. Own15.80%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning11-1350-d Avg4.88200-d Avg5.971yr Est6.33

VRCA News

Verrica Pharmaceuticals to Present New YCANTH® Data Analysis at Two Upcoming Dermatology Conferences
globenewswire.com
Verrica Pharmaceuticals to Present New YCANTH® Data Analysis at Two Upcoming Dermatology Conferences

– Analysis shows YCANTH achieved complete clearance of molluscum contagiosum approximately 4 times f

Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences
globenewswire.com
Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences

– Post-hoc analysis shows YCANTH® drove high rates of complete clearance in molluscum contagiosum pa

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
globenewswire.com
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conferen

WEST CHESTER, Pa., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasd

Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027
globenewswire.com
Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) E

– Per-protocol interim statistical power analysis confirms no additional patients are recommended fo

Verrica Pharmaceuticals Q2 Earnings Call Highlights
marketbeat.com
Verrica Pharmaceuticals Q2 Earnings Call Highlights

Verrica Pharmaceuticals NASDAQ: VRCA reported second-quarter revenue growth in its YCANTH treatment

Verrica Pharmaceuticals Inc. (VRCA) Q2 2026 Earnings Call Transcript
seekingalpha.com
Verrica Pharmaceuticals Inc. (VRCA) Q2 2026 Earnings Call Transcript

Verrica Pharmaceuticals Inc. (VRCA) Q2 2026 Earnings Call Transcript

benzinga.com
Verrica Pharmaceuticals Q2 Adj. EPS $(0.48) Misses $(0.38) Estimate, Sales $5.862M Beat $5.733M Esti

Verrica Pharmaceuticals (NASDAQ:VRCA) reported quarterly losses of $(0.48) per share which missed th

Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026
globenewswire.com
Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Upda

WEST CHESTER, Pa., July 30, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the

12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session

Gainers Autonomix Medical (NASDAQ:AMIX) stock rose 49.1% to $4.1 during Tuesday's after-market

benzinga.com
Verrica Pharmaceuticals Grants Medomie Pharma Rights To Seek Israeli Regulatory Approval For And To

Under the terms of the Agreement, Verrica has granted Medomie an exclusive right to obtain and maint

Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel
globenewswire.com
Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply A

WEST CHESTER, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasda

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 55.8% to $1.11 during Wednesday'

Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts
globenewswire.com
Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COV

- Development Partner Torii Pharmaceutical also recently announced dosing of the first Japanese pati

Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
globenewswire.com
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference

WEST CHESTER, Pa., May 28, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq

benzinga.com
HC Wainwright & Co. Assumes Verrica Pharmaceuticals at Buy, Announces Price Target of $12

HC Wainwright & Co. analyst Raghuram Selvaraju assumes Verrica Pharmaceuticals (NASDAQ:VRCA)

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
globenewswire.com
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Confere

WEST CHESTER, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq

Transcript: Verrica Pharmaceuticals Q1 2026 Earnings Conference Call
benzinga.com
Transcript: Verrica Pharmaceuticals Q1 2026 Earnings Conference Call

Verrica Pharmaceuticals Q1 Earnings Call Highlights
marketbeat.com
Verrica Pharmaceuticals Q1 Earnings Call Highlights

Verrica Pharmaceuticals NASDAQ: VRCA reported higher first-quarter revenue and record demand for its

Verrica Pharmaceuticals Inc. (VRCA) Q1 2026 Earnings Call Transcript
seekingalpha.com
Verrica Pharmaceuticals Inc. (VRCA) Q1 2026 Earnings Call Transcript

Verrica Pharmaceuticals Inc. (VRCA) Q1 2026 Earnings Call Transcript

Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates
zacks.com
Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates

Verrica Pharmaceuticals Inc. (VRCA) came out with a quarterly loss of $0.41 per share versus the Zac

benzinga.com
Verrica Pharmaceuticals Q1 Adj. EPS $(0.41) Misses $(0.38) Estimate, Sales $5.023M Beat $4.520M Esti

Verrica Pharmaceuticals (NASDAQ:VRCA) reported quarterly losses of $(0.41) per share which missed th

Verrica Pharmaceuticals Reports First Quarter 2026 Financial Results
globenewswire.com
Verrica Pharmaceuticals Reports First Quarter 2026 Financial Results

– Company reports record demand for YCANTH® as dispensed applicator units grew to 15,302 in Q1 2026,

Earnings Scheduled For May 12, 2026
benzinga.com
Earnings Scheduled For May 12, 2026

benzinga.com
Verrica Pharma To Present Phase 2 Clinical Data Highlighting Potential Abscopal Effects Of Oncolytic

Phase 2 Data Highlight the Observed Abscopal-like Effect of VP-315 in Non-treated Basal Cell Carcino

Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting
globenewswire.com
Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential A

Phase 2 Data Highlight the Observed Abscopal-like Effect of VP-315 in Non-treated Basal Cell Carcino

Verrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 12, 2026
globenewswire.com
Verrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate Updat

WEST CHESTER, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the

Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual Meeting
globenewswire.com
Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscop

WEST CHESTER, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasd

Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare Conference
globenewswire.com
Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare Conference

WEST CHESTER, Pa., April 06, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasd

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Earnings Scheduled For March 11, 2026
benzinga.com
Earnings Scheduled For March 11, 2026

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session

12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session

Why Heartbeam Shares Are Trading Higher By Around 43%; Here Are 20 Stocks Moving Premarket
benzinga.com
Why Heartbeam Shares Are Trading Higher By Around 43%; Here Are 20 Stocks Moving Premarket

benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session

benzinga.com
Earnings Scheduled For August 12, 2025

benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session

benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session

benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session

benzinga.com
Earnings Scheduled For May 13, 2025

benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session

benzinga.com
Earnings Scheduled For March 11, 2025

benzinga.com
Earnings Scheduled For February 29, 2024

Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings

benzinga.com
Why Quanex Building Products Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In F

Shares of Quanex Building Products Corporation (NYSE: NX) moved lower during Friday’s session after

benzinga.com
Earnings Scheduled For November 9, 2023

Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is expected to report quarterly earnin

benzinga.com
$1M Bet On Verrica Pharmaceuticals? Check Out These 3 Stocks Insiders Are Buying

Although US stocks closed higher on Monday, there were a few notable insider trades.

benzinga.com
Why Ryanair Holdings Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Monday's Mid-Da

Gainers Tupperware Brands Corporation (NYSE: TUP) shares jumped 59% to $1.43 on above-average vo

benzinga.com
Stocks That Hit 52-Week Lows On Wednesday

  On Wednesday, 215 companies set new 52-week lows.

benzinga.com
Stocks That Hit 52-Week Lows On Wednesday

  During Wednesday's trading, 435 companies set new 52-week lows.

benzinga.com
Stocks That Hit 52-Week Lows On Tuesday

  Tuesday's session saw 211 companies set new 52-week lows.

benzinga.com
Stocks That Hit 52-Week Lows On Thursday

  During Thursday, 849 stocks hit new 52-week lows.